Skip to main content
Caplight Logo









VSPharmTech

VSPharmTech

Private
DaeguHealthcare & Life Scienceshttps://vspharmtech.com/

Last Round

Series C

Jun 1, 2026

Est. Valuation

$68.9M

Total Funding Raised

$14.4M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

VSPharmTech is a biotechnology company that develops innovative radiosensitizer drugs designed to enhance the effectiveness of radiation therapy for various types of cancer.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

radiosensitizeroncology therapeuticssmall-molecule drugsclinical-stage biotechdrug discoveryradiation therapyclinical trialsbiotech startupchemoradiotherapyclinical research organizationCROtechnology transferdrug pipelinecancer research

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

VSPharmTech Comparables

Compare VSPharmTech with similar companies based on industry and business-model similarity.

VSPharmTech comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Shuttle Pharmaceuticals Holdings, Inc.
85%
KORTUC INC.
80%
DNA Therapeutics
79%

VSPharmTech Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CJun 1, 2026
Series B ExtensionSep 18, 2025
Series BOct 1, 2023
VC RoundApr 11, 2023
Series AApr 8, 2022
Seed
May 18, 2020

Key People

Founding team and executive leadership

이규훈

Chief Financial Officer

Executive Team

VSPharmTech Investors

Notable investors and investment history

VSPharmTech investors
InvestorRounds
Y&ArcherSeed, Accelerator
SL InvestmentSeries B
IBK CapitalSeries B
Kairos VenturesVC Round
Korea Development BankSeries B
ST Capital (Korea)Series A
Enlight VenturesSeed, Series B, VC Round, Series A, Series B Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jun 19, 2026

    Monthly visitors increased 167% MoM, reaching 650.

  • Jun 1, 2026

    $40M round completed.

VSPharmTech Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

VSPharmTech Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about VSPharmTech's valuation, stock price, and market status.

Firmographic Details

HeadquartersDaegu
Employee Range17
Year Founded2018
Last FundingJun 1, 2026

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?